A new drug for treating type 2 diabetes, which recently received approval from the U.S. Food and Drug Administration (FDA), has shown significant effectiveness in reducing the risk of heart attacks and strokes.
اضافة اعلان
Results from an international clinical trial led by a researcher from Mount Sinai Hospital revealed that the drug Sotagliflozin can greatly reduce the risk of heart attacks and strokes among patients with type 2 diabetes and chronic kidney disease, in addition to other cardiovascular risk factors.
Sotagliflozin belongs to the class of sodium-glucose cotransporter inhibitors (SGLT), working by blocking two proteins known as SGLT1 and SGLT2, which are responsible for transporting glucose and sodium across cell membranes and controlling blood sugar levels.
Unlike other SGLT2 inhibitors, Sotagliflozin inhibits both proteins more effectively.
This study, published in The Lancet Diabetes & Endocrinology, is the first to show that sodium-glucose cotransporter inhibitors have these unique cardiovascular health benefits. The results suggest that Sotagliflozin may become more widely used globally to reduce the risk of fatal cardiovascular events.
Dr. Deepak Bhatt, the study's lead and director of the Heart Failure Hospital at Mount Sinai and professor of cardiovascular medicine at the Icahn School of Medicine, said, "These results demonstrate a new mechanism by blocking SGLT1 receptors (found in the kidneys, intestines, heart, and brain) and SGLT2 receptors (found in the kidneys) using Sotagliflozin, which reduces the risk of heart attacks and strokes." He added, "The benefits observed here differ from those seen with other commonly used SGLT2 inhibitors for treating diabetes, heart failure, and kidney disease."
The study, known as SCORED, analyzed Sotagliflozin's ability to reduce the risk of life-threatening cardiovascular outcomes. It included 10,584 patients with chronic kidney disease, type 2 diabetes, and additional cardiovascular risk factors. The participants were randomly assigned to receive either Sotagliflozin or a placebo, and followed for an average of 16 months.
The results showed that patients who received Sotagliflozin experienced a 23% reduction in the rate of heart attacks, strokes, and cardiovascular-related deaths compared to the placebo group.
Dr. Bhatt added, "Doctors now have a new option to reduce global cardiovascular risks such as heart failure, kidney disease progression, heart attacks, and strokes in patients with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors."
He continued, "This drug has been approved to reduce the risk of cardiovascular-related deaths, heart failure hospitalizations, and emergency visits related to heart failure in patients with heart failure, type 2 diabetes, chronic kidney disease, and other risk factors. These new and important data show that it also reduces the risk of heart attacks and strokes, which may lead to broader use."
